특허 만료 시점의 추정 시장
Year 특허만료제품 수* 2003년 매출 규모(Mil.U$) Expiry Products
규모(Mil.U$)
Nexium, Prevacid, Zoloft, Pravachol, Humulin,
2005 12 22,913 22,913
Combivir, Zoladex, Kaletra, Trizivir, Altace
Paxil/Seroxat, Ambien/Stilnox, Imitrex, Gleevec,
2006 10 15,051 18,061
Lamisil, Pulmicort, Xalatan/Xalacom, Proscar, Viread
Effexor, Fosamax, Risperdal, Zyrtec, Toprol-XL,
2007 12 14,491 20,867 Zometa, Betaseron, Coreg, Plendil, Exelon,
Visudyne, Geodon
Avandia, Depakote, Lamictal, Casodex, Adalat oros,
2008 7 6,049 10,453
Serevent, Zerit
Lipitor, Cozaar/Hyzaar, Aciphex/Pariet, Valtrex,
2009 8 17,438 36,159
Sporanox, Arimidex, Epivir, Xenical
2010 4 5,205 12,952 Taxotere, Protonix, Levaquin/Floxin, Gemzar
Zyprexa, Seroquel, Actos, Actonel, Aprovel/Avapro,
2011 9 11,673 34,855
Atacand, Lescol, Xeloda, Viramune
Diovan/Co-Diovan, Singulair, Allegra/Telfast, Viagra,
2012 10 11,872 42,540
Premarin, Infanrix, Sustiva, Detrol, Zomig, Merrem
Vioxx, Celebrex, Zofran, Humalog, Eloxatin,
2013 8 9,343 40,173
Cerezyme, Genotropin, Zetia
2014 3 2,469 12,739 Copaxone, Lantus, Nasonex
매출 상위 200
Total 83 116,504 매출 상위 200 products품목 매출의 53.4%
products품목의 41.5%
자료:한미약품
